drugset / Trial / NCT00562913
Phase I Study of Sorafenib Dosed Continuously With Cyclophosphamide and Doxorubicin
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Study to access the safety, levels of drug in the blood and tumor effects of sorafenib dosed daily combined with Cyclophosphamide and Doxorubicin in cancer patients
Timeline
- Start
- 2007-12
- Primary completion
- 2009-06
- Completion
- 2010-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sorafenib | Small molecule | 400 mg | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Doxorubicin | Other / unclassified | — | — |